Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.39 |
| ▸ | UBE2M | P61081 | 5/20 | 0.37 |
| ▸ | DCUN1D1 | Q96GG9 | 5/20 | 0.37 |
| ▸ | BMP1 | P13497 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2794724 | 0.93 | KCNH2 (0.40) | KCNH2UBE2MDCUN1D1BMP1OPRM1 | |
| SCHEMBL2797575 | 0.93 | KCNH2 (0.41) | KCNH2UBE2MDCUN1D1NR1H4LMNA | |
| SCHEMBL12002244 | 0.92 | KCNH2 (0.38) | KCNH2UBE2MDCUN1D1BMP1OPRM1 | |
| SCHEMBL2800292 | 0.92 | KCNH2 (0.38) | KCNH2UBE2MDCUN1D1BMP1OPRM1 | |
| SCHEMBL12000215 | 0.92 | UBE2M (0.38) | KCNH2UBE2MDCUN1D1NR1H4LMNA | |
| SCHEMBL2800691 | 0.91 | KCNH2 (0.39) | KCNH2UBE2MDCUN1D1BMP1OPRM1 | |
| SCHEMBL13235062 | 0.91 | KCNH2 (0.40) | KCNH2UBE2MDCUN1D1LMNAHTR1A | |
| SCHEMBL5036632 | 0.91 | KCNH2 (0.43) | KCNH2UBE2MDCUN1D1OPRM1LMNA | |
| SCHEMBL2799184 | 0.90 | HTR1A (0.42) | KCNH2UBE2MDCUN1D1BMP1LMNA | |
| SCHEMBL12002155 | 0.89 | KCNH2 (0.40) | KCNH2UBE2MDCUN1D1BMP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8907001-B2 | Use of a pretreated precipitated silica as a reinforcing filler for silicon elastomer and the curable silicone elastomer compositions thus obtained by cold mixing | RHODIA CHIMIE (FR) | 2014-12-09 | — | — | US | disclosed |
| US-8524738-B2 | Quinolinones and quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-8329694-B2 | Quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-8329694-B2 | Quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-23 | — | — | US | disclosed |
| US-20100168276-A1 | Use of a pretreated precipitated silica as a reinforcing filler for silicon elastomer and the curable silicone elastomer compositions thus obtained by cold mixing | RHODIA CHIMIE (FR) | 2010-07-01 | — | — | US | disclosed |
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20070276078-A1 | Use Of A Pretreated Precipitated Silica As A Reinforcing Filler For Silicone Elastomer And The Curable Silicone Elastomer Compositions Thus Obtained By Cold Mixing | RHODIA CHIMIE (FR) | 2007-11-29 | — | — | US | disclosed |
| WO-2005075551-A1 | USE OF A PRETREATED PRECIPITATED SILICA AS A REINFORCING FILLER FOR SILICONE ELASTOMER AND THE CURABLE SILICONE ELASTOMER COMPOSITIONS THUS OBTAINED BY COLD MIXING | RHODIA CHIMIE (FR) | 2005-08-18 | — | — | WO | disclosed |
| EP-1559744-A1 | Use of a pretreated precipitated silica as a reinforcing filler for silicone elastomer and curable compositions thus obtained | RHODIA CHIMIE (FR) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | ROS1, NOX1, ARG1 | KCNH2 578/4885UBE2M 2433/4885DCUN1D1 1317/4885 |
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | NQO2, ASNS, NDUFS1 | KCNH2 525/4885UBE2M 826/4885DCUN1D1 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.